Hematological and antifungal properties of temporin A and a cecropin A-temporin A hybrid.

• Authors: David Wade , Angela Silveira , Louis Rollins-Smith , Tomas Bergman , Jerzy Silberring , Hilkka Lankinen
• Languages of publication: EN

Abstracts

EN

Temporin A (TA) and a cecropin A-temporin A hybrid peptide (CATA) were synthesized and assayed for their hemolytic, anticoagulant, and antifungal properties. CATA retains significant antifungal activity, is less hemolytic than TA, and inhibits blood coagulation. These results recommend further studies of the biological activities of CATA.

Keywords

EN

cecropin A-temporin A hybrid; coagulation; temporin A; antifungal; hemolysis

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2001
• Volume: 48
• Issue: 4
• Pages: 1185-1189

Dates

published

2001

received

2001-10-1

accepted

2001-11-4

Contributors

author

David Wade

• Peptide Laboratory, Haartman Institute, Helsinki University, Helsinki, Finland

author

Angela Silveira

• King Gustav V Research Institute, Karolinska Hospital, Stockholm, Sweden

author

Louis Rollins-Smith

• Department of Microbiology and Immunology, A-5301 Medical Center North, Vanderbilt University, Nashville, Tennessee, U.S.A.

author

Tomas Bergman

• Protein Analysis Center, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

author

Jerzy Silberring

• Faculty of Chemistry and Regional Laboratory, Jagiellonian University, Kraków, Poland

author

Hilkka Lankinen

• Peptide Laboratory, Haartman Institute, Helsinki University, Helsinki, Finland

References

• 1. Simmaco, M., Mignogna, G., Canofeni, S., Miele, R., Mangoni, M.L. & Barra, D. (1996) Eur. J.Biochem. 242, 788-792.
• 2. Mangoni, M.L., Rinaldi, A.C., Di Giulio, A., Mignogna, G., Bozzi, A., Barra, D. & Simmaco, M. (2000) Eur. J. Biochem. 267, 1447-1454.
• 3. Steiner, H., Hultmark, D., Engström, C, Bennich, H. & Boman, H.G. (1981) Nature 292, 246-248.
• 4. Andreu, D., Ubach, J., Boman, A., Wahlin, B., Wade, D., Merrifield, R.B. & Boman, H.G. (1992) FEBS Lett. 296, 190-194.
• 5. Oh, H., Hedberg, M., Wade, D. & Edlund, C. (2000) Antimicrob. Agents Chemother. 44, 68-72.
• 6. Wade, D., Silberring, J., Soliymani, R., Heikkinen, S., Kilpelainen, I., Lankinen, H. & Kuusela, P. (2000) FEBS Lett. 479, 6-9.
• 7. Nylander, I., Tan-No, K., Winter, A. & Silberring, J. (1995) Life Sci. 57, 123-129.
• 8. Ponti, D., Mignogna, G., Mangoni, M.L., DeBiase, D., Simmaco, M. & Barra, D. (1999) Eur. J. Biochem. 263, 921-927.
• 9. Rollins-Smith, L.A., Doersam, J.K., Longcore, J.E., Taylor, S.K., Shamblin, J.C., Carey, C. & Zasloff, M.A. (2001) Dev. Comp. Immunol. 26, 63-72
• 10. Murray, R.K., Granner, D.K., Mayes, P.A. & Rodwell, V.W. (2000) Harper's Biochemistry25th edn.,pp. 868-869, Appleton & Lange, Stamford, Connecticut.
• 11. Boman, H.G. (2000) Immunol Rev. 173, 5-16.
• 12. Wade, D., Andreu, D., Mitchell, S.A., Silveira, A.M., Boman, A., Boman, H.G. & Merrifield, R.B. (1992) Int. J. Pept. Protein Res. 40, 429-436.
• 13. Daszak, P., Berger, L., Cunningham, A.A., Hyatt, A.D., Green, D.E. & Speare, R. (1999) Emerg.Infect. Dis. 5, 735-748.